Lower prices negotiated for 9 medicines
Last updated: 01 November 2019
You can legally access new medicines, even if they are not approved in your country.
Learn howService Announcement
We are happy to announce that we can present price reductions on 9 medicines that are not yet available to patients and doctors globally for diseases like ovarian cancer, breast cancer and multiple sclerosis. As a social enterprise our commitment is to continuously find, negotiate and provide the lowest prices possible on every medicine that we offer.
There are also price increases on 3 medicines.
How do we do this?
-
We have a dedicated sourcing manager, Sera Gulser, who is dedicated to ensuring we increase accessibility by driving down prices as best we can.
-
We constantly seek new suppliers and new supplies of genuine newly-approved medicines. Additionally, our trusted suppliers also seek lower priced sources themselves.
Supplies of medicines change constantly and sometimes prices also increase. If you have any questions about a price of a medicine please Contact us.
|
Medicine |
Price Change % |
New Price |
|
Spinraza (nusinersen) 2.4 mg/ml in 1 vial of 12mg/5ml |
-8.41% |
€99,000 |
|
Opdivo (nivolumab) 10 mg/ml in 1 vial of 4 ml |
-7.67% |
€540.50 |
|
Mavenclad (cladribine) 10 mg x 1 tablet |
-4.05% |
€2,612.80 |
|
Ibrance (palbociclib) 125 mg x 21 capsules |
-13.9% |
€4,594.25 |
|
Ibrance (palbociclib) 100 mg x 21 capsules |
-13.90% |
€4,594.25 |
|
Ibrance (palbociclib) 75 mg x 21 capsules |
-13.90% |
€4,594.25 |
|
Zejula (niraparib) 100 mg x 56 capsules |
-2.01% |
€8,395.00 |
|
Zejula (niraparib) 100 mg x 84 capsules |
-0.46% |
€12,420.00 |
|
Calcort (deflazacort) - 6 mg x 20 tablets |
-13.51% |
€11.44 |
|
Lynparza (olaparib) - 50 mg x 448 capsules |
+6.59% |
€6,619.40 |
|
Taltz (ixekizumab) - 80 mg x 2 syringes or pens |
+7.84% |
€2,750.80 |
|
Taltz (ixekizumab) - 80 mg x 3 syringes or pens |
+8.87% |
€4,134.25 |
